John Reese
Validea
Jim Powell
Global Changes & Opportunities Report
Timothy Lutts
Cabot Stock of the Month
John Buckingham
The Prudent Speculator

4 capital gain favorites for the second half


Bookmark and Share
by Richard Moroney, editor Upside Stocks

Richard MoroneyShares of many high-quality small and midsize companies are trading at attractive valuations, and our Quadrix rating system continues to do a good job of isolating winners. You can build a relatively diversified portfolio of smaller stocks without settling for second-tier names.

We see appealing stocks in several groups likely to outperform over the next six to 12 months. Here's four favorites for capital gains the second half of the year: AmTrust Financial Services (AFSI),  Bio-Reference Laboratories (BRLI), Dillard’s (DDS) and Dolby Laboratories (DLB).

Amtrust FInancial has surged 22% so far in 2012 but still has plenty of upside. The specialty insurer is benefiting from favorable pricing, strong client retention, and prudent risk management.

The company focuses on insurance for workers compensation and extended product warranty coverage. Recent results reflect higher fee income and improved underwriting results.  

AmTrust stands tall on two important operating metrics. On March 31, per-share book value was $15.91, up 24% from a year earlier. Over the last three years, book value has grown at a 32% annualized rate.

Return on equity was 19% in the March quarter, versus an average of 7.5% for the 57 property and casualty insurers in Quadrix. AmTrust, capable of increasing 15% to 20% in the next 12 months, is a Best Buy.

Bio-Reference Labs has rallied 28% over the past month, fueled by a combination of strong April-quarter results and takeover speculation.

A leading provider of medical testing services, Bio-Reference earned $0.33 per share, up 27% and a penny above the consensus. Revenue advanced 19%, partly reflecting a 16% increase in patients served.

News that rival Medtox agreed to be acquired by Laboratory Corp. of America for a nearly 40% premium helped propel shares of Bio-Reference higher.  

Increased contributions from high-end medical tests and market-share gains should help sustain growth. For fiscal 2012 ending October, per-share earnings are expected to reach $1.46, up 26% on an 18% sales increase.

For fiscal 2013, per-share profits are expected to climb 19% on a 16% sales gain. Trading at 20 times trailing earnings -- a 20% discount to its 10-year average P/E -- Bio-Reference is a Best Buy.

With more than 300 department stores and clearance centers in 29 states, Dillard’s has a strong and growing market position. In recent years the retailer has im- proved same-store sales, inventory turnover, and revenue per square foot.

Dillard’s Overall Quadrix score of 99 ranks among the top 1% of U.S.-traded stocks and places it No. 1 among the nine department-store stocks in our research universe. Dillard’s earns a 75 or higher in five of the six Quadrix categories.

The company has delivered three straight positive profit surprises, surpassing the consensus by an average of 26%. At less than 14 times trailing earnings, Dillard’s trades at a 25% discount to its five-year average. Dillard’s is being upgraded to Best Buy.

Dolby Laboratories fortunes are entwined with consumer electronics, including tablet computers and smartphones, that play digital content.

The company’s technologies help maintain sound quality while enabling content to fit within the stor- age capacity of a device. Many movie, television, music, and video game studios produce content encoded with Dolby technologies.

The company recently unveiled a new audio system for theaters, with Disney-Pixar’s Brave the first feature film mixed for the new platform. Microsoft will use Dolby’s audio technology when it launches the Windows 8 operating system later this year.

Dolby earns an Overall score of 92, with strong scores for Quality (93) and Financial Strength (95). Shares seem unduly cheap at 14 times trailing earnings, especially considering the balance sheet has more than $10 per share in cash. The stock is a Best Buy.

Learn more about this financial newsletter at Richard Moroney's Upside Stocks.

Related articles:

Advertisement
Banner
News Flash

United Natural: A play on Whole Foods
by Mark Skousen, editor Hedge Fund Trader Alert

We’ve recommended Whole Foods Market (WFM) from time to time, and the stock has moved up sharply in the past three years, but I’d like to suggest an alternative -- one of Whole Foods’ primary suppliers, United Natural Foods (UNFI).


Read more...

 

Timing expert eyes India
by Sy Harding, editor Street Smart Report

The money flow and momentum reversals in India's Bombay Index have now been enough to trigger buy signals on intermediate-term indicators. With this new buy signal, we have added a position in the iShares India 50 ETF (INDY) to our portfolio.


Read more...


   

Value investor goes with Guess
by Charles Mizrahi, editor Hidden Values Alert

Guess?, Inc. (GES) is a holding in our special situation portfolio; its strong product quality has created brand name recognition and a loyal consumer following.


Read more...

 

MGAM: Bingo, lotteries, casinos
by Jim Oberweis, Jr., editor The Oberweis Report

Multimedia Games Holding Company (MGAM) makes innovative gaming systems for Native American and commercial casino operators in North America, lottery operators, and charity and commercial bingo operators.


Read more...

 

Fidelity expert: Bowers' bond bets
by Jack Bowers, editor Fidelity Monitor & Insight

If you’ve been worried that the bond market might take a big hit, you can relax. Indeed, while bond funds may lag stock funds over the next 5-10 years, they still have a decent shot at keeping up with inflation, and they remain an excellent way to cut risk in a blended portfolio.


Read more...

 

Tesla: 'Out of the ball park'
by Timothy Lutts. editor Cabot Stock of the Month

Tesla (TSLA), our previously featured Stock of the Month and our top stock pick for 2013, knocked the ball out of the park in its latest quarter. The company exceeded analysts' expectations on all counts: cars sold, revenues, earnings, gross margins and more.


Read more...

 

5 ways to speculate on Cuba
by Jim Powell, editor Global Changes & Opportunities Report

With the death of Hugo Chavez in March, and Venezuela’s economic decline, the heavily subsidized oil lifeline is likely to be cut or sharply reduced. I think the resulting energy squeeze will force Cuba to allow greater foreign trade and investment.


Read more...

 

Big gains in nanotechnology?
by Doug Fabian, editor Making Money Alert

The nanotechnology niche focuses on very small, even microscopic, technology. Nanotech has produced technological developments in medicine (lasers), electronics (ink jet systems) and biomaterials (chemical and bio-detectors).


Read more...

 

Gold: Reasons for continued caution
by Jim Stack, editor Investech Market Analyst

In October 2011, we questioned the run-up in gold prices to $1,895 an ounce and called prices “bubblish”.  We were criticized for not understanding the new paradigm. Nonetheless, the price of gold has fallen significantly, and I feel more comfortable sharing my personal perspective of what lies ahead.


Read more...

 

Buffett's Berkshire is still a buy
by Geoffrey Seiler, editor BullMarket.com

Recommended List selection Berkshire Hathaway (BRK.B) reported a 51% increase in net income for the first quarter, powered by profits from its extensive insurance businesses and strong results from the railroad unit.


Read more...

 



Banner



Close
Select Offer: Schwab Options Market Commentary